- Home
- MCRB vs AVTX Comparison
MCRB vs AVTX Comparison
Compare MCRB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- AVTX
- Stock Information
- Founded
- MCRB 2010
- AVTX 2011
- Country
- MCRB United States
- AVTX United States
- Employees
- MCRB N/A
- AVTX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- AVTX Health Care
- Exchange
- MCRB Nasdaq
- AVTX Nasdaq
- Market Cap
- MCRB 144.6M
- AVTX 138.8M
- IPO Year
- MCRB 2015
- AVTX 2015
- Fundamental
- Price
- MCRB $20.76
- AVTX $13.49
- Analyst Decision
- MCRB Hold
- AVTX Strong Buy
- Analyst Count
- MCRB 4
- AVTX 9
- Target Price
- MCRB $14.33
- AVTX $30.14
- AVG Volume (30 Days)
- MCRB 227.9K
- AVTX 447.0K
- Earning Date
- MCRB 11-12-2025
- AVTX 11-06-2025
- Dividend Yield
- MCRB N/A
- AVTX N/A
- EPS Growth
- MCRB N/A
- AVTX N/A
- EPS
- MCRB 10.22
- AVTX N/A
- Revenue
- MCRB N/A
- AVTX $441,000.00
- Revenue This Year
- MCRB N/A
- AVTX N/A
- Revenue Next Year
- MCRB N/A
- AVTX N/A
- P/E Ratio
- MCRB $2.05
- AVTX N/A
- Revenue Growth
- MCRB N/A
- AVTX N/A
- 52 Week Low
- MCRB $6.53
- AVTX $3.39
- 52 Week High
- MCRB $24.67
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- MCRB 59.57
- AVTX 67.21
- Support Level
- MCRB $19.14
- AVTX $12.41
- Resistance Level
- MCRB $21.97
- AVTX $14.73
- Average True Range (ATR)
- MCRB 1.52
- AVTX 0.94
- MACD
- MCRB 0.22
- AVTX 0.14
- Stochastic Oscillator
- MCRB 78.90
- AVTX 74.50
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).